Intranasal immunisation with defective adenovirus serotype 5 expressing the Venezuelan equine encephalitis virus E2 glycoprotein protects against airborne challenge with virulent virus

Phillpotts, R. J.; O’Brien, Lyn M.; Appleton, Richard; Carr, Silvana; Bennett, Alice M.

doi:10.1016/j.vaccine.2004.06.056

Cited by 47 publications

(39 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3B). This finding is different from that obtained in studies of VEEV (12,13), in which the E3-E2-6K-coding region of VEEV gave good protection against challenge with the homologous strain. The presence of the 6K gene, which might help with the folding and the processing of E3-E2, may account for this difference.…”

contrasting

confidence: 99%

Identification of Western Equine Encephalitis Virus Structural Proteins That Confer Protection after DNA Vaccination

Gauci

Rayner

et al. 2010

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

contrasting

confidence: 99%

Identification of Western Equine Encephalitis Virus Structural Proteins That Confer Protection after DNA Vaccination

Gauci

Rayner

et al. 2010

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…Adenovirus subtype 5 vectors with E1 and E3 deleted were produced using the AdEasy (Qbiogene, Carslbad, CA) kit as described in the manufacturer's handbook. The shuttle vector pShuttle-CMV (Qbiogene, Quebec, Canada), expressing HIV gp120 (NIH AIDS Reference and Reagent Program), codon-optimized HA (A/ Indo/05/2005 (A/Indo), synthesized by CelTek, [Nashville, TN]), and Venezuelan equine encephalomyelitis (VEE) virus structural genes E3, E2, and 6K (12), was constructed by standard molecular methods. A separate vector expressing the dsRNA species luc1 under the cytomegalovirus (CMV) promoter was made by overlapping oligonucleotide primers GAAACGATA TGGGCTGAATAC and a short 6-bp spacer between them that forms the loop of the hairpin.…”

Section: Methodsmentioning

confidence: 99%

An Adenovirus-Based Vaccine with a Double-Stranded RNA Adjuvant Protects Mice and Ferrets against H5N1 Avian Influenza in Oral Delivery Models

Scallan

Tingley

Lindbloom

et al. 2013

Clin Vaccine Immunol

View full text Add to dashboard Cite

An oral gene-based avian influenza vaccine would allow rapid development and simplified distribution, but efficacy has previously been difficult to achieve by the oral route. This study assessed protection against avian influenza virus challenge using a chimeric adenovirus vector expressing hemagglutinin and a double-stranded RNA adjuvant. Immunized ferrets and mice were protected upon lethal challenge. Further, ferrets immunized by the peroral route induced cross-clade neutralizing antibodies, and the antibodies were selective against hemagglutinin, not the vector. Similarly, experiments in mice demonstrated selective immune responses against HA with peroral delivery and the ability to circumvent preexisting vector immunity.

show abstract

“…VEEV strain Trinidad donkey (TrD), from serogroup IA/B, was supplied by Dr R. E. Shope (University of Texas Medical Branch, Galveston, TX, USA). A virulent virus stock was prepared and the titre determined as described by Phillpotts et al (2005). All work with VEEV was carried out under UK Advisory Committee on Dangerous Pathogens Level 3 containment.…”

Section: Methodsmentioning

confidence: 99%

“…of 1000) plus Ad5-mIFNa (m.o.i. of 200) and incubated for 48 h. Antigen was then prepared from cells as described by Phillpotts et al (2005) and VEEV proteins were detected by using 10 mg 1A4A1 ml 21 .…”

mentioning

confidence: 99%

Alpha interferon as an adenovirus-vectored vaccine adjuvant and antiviral in Venezuelan equine encephalitis virus infection

O’Brien

Perkins

Williams

et al. 2009

Journal of General Virology

View full text Add to dashboard Cite

There are no widely available vaccines or antiviral drugs capable of protecting against infection with Venezuelan equine encephalitis virus (VEEV), although an adenovirus vector expressing VEEV structural proteins protects mice from challenge with VEEV and is potentially a vaccine suitable for human use. This work examines whether alpha interferon (IFN-α) could act as an adjuvant for the adenovirus-based vaccine. IFN-α was either expressed by a plasmid linked to the adenovirus vaccine or encoded by a separate adenovirus vector administered as a mixture with the vaccine. In contrast to previous reports with other vaccines, the presence of IFN-α reduced the antibody response to VEEV. When IFN-α was encoded by adenovirus, the lack of a VEEV-specific response was accompanied by an increase in the immune response to the adenovirus vector. IFN-α also plays a direct role in defence against virus infection, inducing the expression of a large number of antiviral proteins. Adenovirus-delivered IFN-α protected mice from VEEV disease when administered 24 h prior to challenge, but not when administered 6 h post-challenge, suggesting that up to 24 h is required for the development of the IFN-mediated antiviral response.

show abstract

Intranasal immunisation with defective adenovirus serotype 5 expressing the Venezuelan equine encephalitis virus E2 glycoprotein protects against airborne challenge with virulent virus

Cited by 47 publications

References 38 publications

Identification of Western Equine Encephalitis Virus Structural Proteins That Confer Protection after DNA Vaccination

Identification of Western Equine Encephalitis Virus Structural Proteins That Confer Protection after DNA Vaccination

An Adenovirus-Based Vaccine with a Double-Stranded RNA Adjuvant Protects Mice and Ferrets against H5N1 Avian Influenza in Oral Delivery Models

Alpha interferon as an adenovirus-vectored vaccine adjuvant and antiviral in Venezuelan equine encephalitis virus infection

Contact Info

Product

Resources

About